USFDA issues response letter for new drug application for insulin glargine: Biocon

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32i4oii
via IFTTT